An observational study in Cardiac Arrest (CA), Anoxic Brain Injury and Comatose Survivors of Cardiac Arrest, sponsored by University of Aarhus. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by University of Aarhus · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Heart Arrest with a site in Denmark — 6 open to participants now, 11 under way, none of them phase 3. Heart Arrest · Denmark.
Among the 36 studies in Heart Arrest with a site in Denmark, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2025, is one of 10 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 35th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →6 of the 36 studies in Heart Arrest with a site in Denmark are open now. Recruiting first, the newest first:
Lars Wiuff Andersen · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark, Norway
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18–65
Emergency Medical Services, Capital Region, Denmark · Sites in Denmark
Ages 8+
Bo Gregers Winkel · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 274 across the 26 interventional studies, 157 across the 10 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 36 has an industry lead sponsor. The 10 most frequent:
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
University of Aarhus has 8 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Arrest with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04446585Emergency Medical Services, Capital Region, DenmarkCardiac Arrest in Residential Areas With Mobile First-responder Activation | 2027-01 |
| NCT06809309University of AarhusThe Ventilation During In-hospital Cardiac Arrest Study | 2027-04 |
| NCT05173740Rigshospitalet, DenmarkRehabilitation for Survivors of Out-of-hospital Cardiac Arrest | 2027-07-31 |
| NCT06979700University of AarhusEarly WAKE-up Predictors After Out-of-Hospital Cardiac Arrest | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Heart Arrest with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
WAKE-OHCA is a prospective observational substudy of the Danish Out-of-Hospital Cardiac Arrest (DANOHCA) trial, identifier NCT05895838. The aim is to collect early neuromonitoring data to identify key predictors of successful wake-up.
Background:
Post-resuscitation care following out-of-hospital cardiac arrest remains a critical area of research to optimize neurological recovery and cardiovascular outcomes. Recent findings from the Targeted Temperature Management (TTM) trials have led to the discontinuation of therapeutic hypothermia in Denmark, eliminating the need for deep sedation. The optimal sedation strategy in post-resuscitation care remains unknown, with sedation hypothesized to be neuroprotective controlling intracranial pressure but also known to be harmful and associated with adverse outcomes such as delirium, ventilator associated pneumonia, venous thromboembolism, prolonged intensive care unit (ICU) stay, delayed mobilization and patient prognostication.
Though there is emerging interest in early weaning from sedation within post-resuscitation care, limited data exist on its feasibility, prognostic implications and cost-effectiveness. Certain neuromonitoring modalities including automated pupillometry, transcranial doppler and electroencephalography (EEG) have shown promising prognostic properties, also in predicting favorable outcomes. However, sparse literature exists on early (\<6 hours) prognostication related to length of sedation, and further knowledge in this area is needed to support clinical decision making.
The Danish Out-of-Hospital Cardiac Arrest (DANOHCA) study (NCT05895838) is an on-going multicenter randomized trial enrolling 1,000 participants to early wake-up (\<6 hours) or standard (28-36 hours) length of sedation. This provides an opportunity to further understand neuroprognostication related to length of sedation in post-resuscitation care.
Aim and hypothesis:
This present study is designed within the context of the DANOHCA trial with the aim of identifying patient and neuromonitoring predictors of successful early and late wake-up.
The hypothesis is: Specific patient variables and neuromonitoring parameters are associated with successful wake-up.
Materials and Methods:
WAKE-OHCA will be conducted as a two-part analysis with 1) entire DANOHCA cohort (n=1,000 participants) with ICU admission data and 2) neuromonitoring data collected within the ICU on the patient cohorts at two Danish university hospital sites (Aarhus University Hospital and Rigshospitalet) during the study inclusion period (anticipated n=250 participants, with the exception of n=100 participants for EEG measurements, as these will only be performed at Aarhus University Hospital site).
DANOHCA inclusion criteria are: Out-of-hospital cardiac arrest of a presumed cardiac cause, age > 18 years, sustained return of spontaneous circulation for more than 20 minutes, unconscious upon admission.
The first part will include baseline characteristics, cardiac arrest data, and initial biochemistry. Data is collected from Danish prehospital patient journal (PPJ), electronic patient journals (EPJ, Sundhedsplatformen), Danish cardiac arrest registry and DANOHCA patient database.
The second part will include the following non-invasive neuromonitoring data collected prospectively at 0-6 hours, 20-28 hours, 44-52 hours and 66-72 hours after enrolment:
These will provide insight on early neurological status and recovery patterns, cerebral hemodynamics and intracranial pressure. Neuromonitoring data will only be collected on participants that are still comatose. Clinicians will be blinded from collected data, and it will have no impact on participants' treatment.
Automated pupillometry will be done with a NeurOptics NPi-200 pupillometer (NeurOptics, Irvine, California, USA). Transcranial doppler and ONSD measurements will be conducted with a Vivid S70N (GE Healthcare, Chicago, IL, USA) and analysed using Echopac (GE Healthcare, Chicago, IL, USA). EEG measurements will be done with Mindray BeneVision N-series with an aEEG module (Shenzhen Mindray Bio-Medical Electronics Co., Nanshan, Shenzhen, China).
Logistic regression analysis will be conducted to explore the association between participant and neuromonitoring variables and successful wake-up with unsuccessful wake-up as reference group. Secondary analyses will investigate how neuromonitoring variables perform in predicting patient outcomes (mortality, neurological outcome) in the early and late wake-up groups as well as how serial neuromonitoring variables are associated with successful wake-up at later stages.
Significance:
By identifying key predictors of early wake-up success, this project may refine patient selection, optimize individualized treatment, and enhance prognostication. Insights into neuromonitoring could improve clinical decision-making and reduce unnecessary sedation, minimizing associated complications.
Patients enrolled in the DANOHCA trial at Aarhus University Hospital and Rigshospitalet.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment for both pupils and include: Neurological pupil index, pupillary size, pupillary minimum diameter, pupillary constriction amplitude, pupillary constriction velocity, pupillary maximum constriction velocity, pupillary latency and pupillary dilation velocity.
Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both middle cerebral arteries and include the following: Peak systolic velocity, end diastolic velocity, mean velocity, pulsatility index and resistance index.
Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both eyes using ultrasound and include the following: optic nerve sheath diameter of right and left side and mean optic nerve sheath diameter.
Continuous 4-channel EEG will be established on participants as soon as possible within 0-6 hours. EEG will be stopped at successful extubation or when 72 hours has passed since study inclusion. EEG Reactivity will be performed on comatose participants at the following times: 0-6, 20-28, 44-52 and 66-72 hours after study inclusion. Reactivity includes 7 standardized stimuli, including 1 visual, 3 auditive and 3 pain stimuli. EEG data will be reviewed in Stratus EEG Analysis (Kvikna Mediacal ehf. version 5.1). Timestamps for EEG-reactivity will be manually inserted in the file. EEG Reactivity will be analysed quantitatively by power spectrum analyses performed in LabVIEW 2016 (National Instruments) according to the principles of a previous method (PMID: 36041343). Background activity within 5 minutes following reactivity stimuli, prioritizing time periods without artifacts, will be analysed by power spectrum analyses, Mindray quantitative analysis and manually analyzed by experts.
Number of patients with successful wake-up
Defined as awake and successfully extubated.
Time frame: 0-6 hours or 28-36 hours according to DANOHCA randomization.
Number of patients with successful delayed wake-up
Defined as awake and successfully extubated later than according to DANOHCA randomization.
Time frame: Up to 90 days.
Duration of intubation
Assessed as the duration of intubation from randomization till extubation during initial ICU stay (oral and tracheostomy combined).
Time frame: Up to 90 days.
Days alive outside hospital
Counted as days alive outside of hospital after discharge.
Time frame: 30 days.
30-day mortality
Number of patients dying from all causes.
Time frame: 30 days.
90-day mortality
Number of patients dying from all causes.
Time frame: 90 days.
Length of ICU stay
Assessed as the initial ICU length of stay.
Time frame: From randomization till discharge from the ICU, up to 90 days.
Length of hospital stay
Assessed as the hospital length of stay (including in-patient rehabilitation and transfer to referral hospital).
Time frame: From randomization till discharge from hospital or in-patient rehabilitation, up to 90 days.
Cerebral Performance Category (CPC)
CPC score at ICU discharge, at hospital discharge, and at ambulatory follow-up (scheduled visit at 3 to 6 months after the cardiac arrest). The CPC score ranges from 1 to 5 with higher scores indicating worse outcomes.
Time frame: Up to 6 months.
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.
Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 28 months is below that.
Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.